A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Octapharma's balanced portfolio built on a very special juice
2013
The Journal of Haemophilia Practice
Preserved Fulltext
Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair
doi:10.17225/jhp.00023
fatcat:dhyuvuuxs5asrpu2g2yktvifum